Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.5, 2005-10, pp. : 391-409

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab tallies up in HER2+ breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Trastuzumab tallies up in HER2+ breast cancer

Inpharma, Vol. 1, Iss. 1614, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K. Perry C.M.

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

By Essers Brigitte A.B. Seferina Shanley C. Tjan-Heijnen Vivianne C.G. Severens Johan L. Novák Annoesjka Pompen Marjolein Oron Ulrich H. Joore Manuela A.

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 375-380

Blackwell Publishing

Access to resources Recommend Favorite